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Exposure to arsenic (As) through drinking water is a substantial problem worldwide. The methylation of As, a reactive metalloid,
generates monomethyl- (MMA) and dimethyl-arsenical (DMA) species. The biochemical pathway that catalyzes these reactions,
one-carbon metabolism, is regulated by folate and other micronutrients. Arsenic methylation exerts a critical inﬂuence on both
its urinary elimination and chemical reactivity. Mice having the As methyltransferase null genotype show reduced urinary As
excretion, increased As retention, and severe systemic toxicity. The most toxic As metabolite in vitro is MMA
III, an intermediate
in the generation of DMA
V, a much less toxic metabolite. These ﬁndings have raised the question of whether As methylation is
a detoxiﬁcation or bioactivation pathway. Results of population-based studies suggest that complete methylation of inorganic As
to DMA is associated with reduced risk for As-induced health outcomes, and that nutrients involved in one-carbon metabolism,
such as folate, can facilitate As methylation and elimination.
1.Introduction
Arsenic (As) is a naturally occurring element commonly
present in environmental sources such as air, water, and soil
[1]. Through processes that are incompletely understood,
As in soil can be mobilized leading to enrichment of As
in groundwater. While drinking water is the most common
source of exposure, other sources include As from mining
and smelting, wood preservatives, pesticides, and foods irri-
gated and/or prepared with As-contaminated water. Current
estimates suggest that roughly 140 million people in Bang-
ladesh, India, Vietnam, Nepal, and Cambodia are drinking
w a t e rw i t hA sc o n c e n t r a t i o n su pt o1 0 0t i m e st h eW o r l d
Health Organization (WHO) and USA Environmental Pro-
tection Agency (EPA) guideline of 10µg/L [2, 3]. Chile,
Mexico, China, and Taiwan also have As in groundwater that
is used for drinking. In comparison to the situation in South
and East Asia, the magnitude of the problem in the USA
is rela- tively small. Nevertheless, the US Geological Survey
estimates that 42 million Americans obtain their drinking
water from household wells, and roughly 15% of these wells
exceed the WHO guideline, indicating that a large number of
USA residents are exposed to excess As from household wells
[4]. In addition, not all municipalities are yet in compliance
with the EPA requirements, with up to 8% of all public water
supplies exceeding 10µgA s / L .
IndividualschronicallyexposedtoAsareatincreasedrisk
for various cancers, including cancers of the skin (Bowen’s
disease, basal cell carcinomas, and squamous cell carcino-
mas) [5], lung, bladder, and liver [6]. Chronic As exposure
is a major risk factor for ischemic heart disease [7]a n d
Blackfoot Disease, the latter a form of severe peripheral
vascular disease associated with systemic atherosclerosis, dry
gangrene, and spontaneous amputations of aﬀected extrem-
ities [8].
Arsenic is metabolized via methylation and understand-
ing of the importance of As methylation has advanced sub-
stantiallyinthepastdecade.Thispaperprovidesanoverview2 Journal of Toxicology
of what is now known about As methylation, including
the details of the methylation pathway and the inﬂuence of
methylation on As elimination, toxicity, and risk for As-
induced health outcomes. We will also discuss the accu-
mulating evidence suggesting that nutritional manipulation
of one-carbon metabolism can improve As methylation
capacity.
1.1. As Methylation. The predominant forms of As in drink-
ingwaterarearsenate(AsV)andarsenite(AsIII).Mostspecies
methylate these inorganic As (InAs) species to varying
degrees in a process commonly thought to involve alternate
reduction and oxidative methylation reactions in a model
originally proposed by Challenger roughly 70 years ago [9,
10] (Figure 1). In this model, InAsIII serves as a substrate
for As methyltransferase (AS3MT), an enzyme identiﬁed
by Thomas’s group in 2002 [11, 12]. AS3MT catalyzes
the oxidative methylation of InAsIII to methylarsonic acid
(MMAV) using S-adenosylmethionine (SAM) as a cosub-
strate. MMAV is reduced to MMAIII in a reaction that can be
catalyzed by AS3MT using reducing equivalents provided
by thioredoxin [13]. Although earlier reports identiﬁed
MMAV reductase,amemberoftheglutathione-S-transferase
superfamily (GSTΩ)[ 14, 15] as being capable of catalyzing
this reduction, studies employing GSTΩ knockout mice
indicate this function is not unique to GSTΩ (Chowdhury
UK 2006). The methylation of MMAIII by AS3MT yields
dimethylarsinic acid (DMAV), which is considerably less
toxic than pentavalent or trivalent InAs or MMA. While
other methyltransferase enzymes have been identiﬁed which
arecapableofcatalyzingthesemethylationreactions[16,17],
AS3MT catalyzes the formation of MMAV and DMAV with
a kM in the nM range [12]. Although methylation of As is
generally considered to be primarily hepatic, AS3MT mRNA
has also been detected in rat kidney, adrenal gland, lung,
urinary bladder, heart, and brain [12].
There are controversies related to As metabolism and
toxicity that warrant discussion. For example, DMAV can be
reduced, and some investigators have reported that DMAIII
may represent a signiﬁcant proportion of total urinary As
[18–20]; however the potential for artifact is high for several
reasons [21]. First, DMAIII in urine is highly labile; Gong
et al. have demonstrated that it is completely oxidized
to DMAV within 24 hours when stored at −20◦C[ 22].
Second, the method employed in these studies [18, 19]t o
synthesize the purported chromatographic standard for
DMAIII, that is, treatment of DMAV with metabisulﬁte and
thiosulfate,infactdoesnotgenerateDMAIII,butratherthio-
DMAV [23]. Third, while Valenzuela et al. used appropri-
ate DMAIII standards [20], the hydride analyte ultimately
detected by their assay could be generated from either
DMAIII or thio-DMA [21]. This thioarsenical species has
recently been found to be present as a relatively minor
(roughly 5% of total uri- nary As) arsenical species in urine
of Bangladeshi women [21]. For these reasons, it is likely that
the chromatographic peak assigned as DMAIII in population
studies was actually thio-DMAV. While the toxicity of thio-
DMAV has not been well characterized, Francesconi’s group
has shown that thio-DMAV reduces HepG2 cell viability to a
greater extent than DMAV at concentrations ranging from
0 . 1t o1 m M[ 21]. A lesser issue relates to trimethylarsine
oxide which can be formed under some assay conditions, but
its production is strongly inhibited by the presence of GSH
[11], and measurable amounts are generally not thought to
be produced by humans in vivo.
A second model of As methylation proposed by
Hayakawa et al. in 2005 suggests that trivalent arsenical-
thiol complexes are the obligate substrates for AS3MT which
catalyzes nonoxidative methylation reactions [24]. Work by
Naranmandura and colleagues suggests a reductive methyla-
tion brought about by the transfer of an unshared electron
pair from As to a methylation and concurrent reduction of
As by conjugated GSH [25]. Future studies characterizing
the structure and function of the AS3MT enzyme will be
required to fully characterize the details of this metabolic
process.
1.2. The Role of Methylation in As Elimination. Recent
work by Thomas’s group using AS3MT knockout mice has
conﬁrmed the crucial role of AS3MT in the methylation
and excretion of As. After a single oral dose of 0.5mg of
arsenic as arsenate per kg body weight, AS3MT knockout
m i c es h o w e dar e d u c e dp r o p o r t i o no fm e t h y l a t e da r s e n i c a l s
in both liver and urine at 2 and 24 hours compared to
wild-type mice [26]. AS3MT knockout mice also retained
a higher percentage of the initial body burden of As in the
liver, kidneys, urinary bladder, lungs, heart, and carcass at
24 hours than did wild-type mice. In a subsequent study in
which mice received 10 daily oral doses of 0.5mg of arsenic
as arsenate per kilogram body weight, the AS3MT knockout
mice showed reduced whole body clearance of As 24 hours
after the ﬁnal dose compared to wild-type mice (40% versus
90% clearance) [27]. During the clearance phase, DMA
accounted for 6.9% of urinary As at 240 hours after the
ﬁrst dose in the knockout mice as compared to 84% in the
wild-type mice. The AS3MT knockout mice also showed
higher fractions of the body burden of As in skin, liver,
and urinary bladder as compared to wild type. Although
the AS3MT gene resulted in a substantially reduced capacity
for As methylation, methylated arsenicals were still observed
in urine and tissues of AS3MT knockout mice. In fact, the
AS3MT knockout mice had a higher proportion of MMA
in both urine and liver than did wild type [26]. In a study
whichunderscoresthecriticalroleofAS3MTinAsexcretion,
knockout mice exposed to 100 or 150ppm arsenite via diet
showed severe, and often lethal, systemic toxicity after only
one week of exposure [28]. Given that MMAIII is the most
toxic As metabolite, an interesting question that arises from
this work is whether the toxicity observed in the knockout
mice is at least in part due to the increased proportion of
MMA. The work of Thomas and colleagues also strongly
suggests that there are alternate pathways for methylation
of InAs to MMA. Indeed, this group recently reported the
in-vitro conversion of arsenate to oxy- and thioarsenicals,
including MMAV, by anaerobic microbiota of mouse cecum
[29]. There may also be other enzymes capable of catalyzing
these reactions.Journal of Toxicology 3
N N
N N N
N
N
N
OH
OH
OH
OH
OH OH
OH OH
OH
OH
OH HO
HO
HO
HO
O
O O
O
H2N
NH2 NH2
NH2
S
S+ −O
AsIII
AsIII
AsIII
Trx-(SH)2 Trx-(S)2
DMAV AsV
AsV
AsV AsV O= O= O= − O
GSH GSSG
SAM SAH SAM SAH
AS3MT AS3MT
MMAV III MMA
CH3 CH3
CH3
CH3
CH3
Figure 1: Arsenic metabolism. Arsenic in tubewells in Bangladesh is predominantly arsenite. Arsenic (+3 oxidation state) methyltransferase
(AS3MT) catalyzes the oxidative methylation of arsenite using s-adenosylmethionine (SAM) as the methyl donor, forming methylarsonic
acid (MMAV), and s-adenosylhomocysteine (SAH). MMAV is reduced to methylarsonous acid (MMAIII) before a subsequent oxidative
methylation step yielding dimethylarsinic acid (DMAV) and SAH.
The relative toxicities of the diﬀerent As species are
related to their chemical reactivity, but also to their physi-
ologic half lives. Human retention studies employing single
oral doses of 74As as arsenic acid or AsO(OH)3 to human
volunteers indicate that arsenicals are eliminated with a
three-component exponential decay pattern: 65.9% with a
half life of 2 days, 30.4% with a half life of 9.5 days, and 3.7%
w i t hah a l fl i f eo f3 8d a y s[ 30]. However, when considering
populations that have been exposed to InAs for many years,
thesehalflivesderivedfromsingle-doseexperimentsmustbe
viewed with caution since steady-state tissue concentrations
were not achieved, and a “deep compartment” with a much
longerhalflifecouldhavebeenmissed.Indeed,inmice,some
InAs deposits in bone [31], suggesting that a longer terminal
half life is likely. Similar patterns of elimination are observed
in rabbits and hamsters. The initial half lives of MMA and
DMA in hamsters are very short (7.4 and 5.6h, respectively)
[32], indicating the importance of As methylation for the
facilitation of As elimination. The speciﬁc half lives of
MMA and DMA in humans have not been determined,
and their half lives under steady-state conditions may diﬀer
from those calculated using tracer kinetics with single oral
doses. Somewhat remarkably, our understanding of the renal
mechanismsofAsexcretionislimitedtoearlystudiesrelating
transport of arsenate (InAsV) to phosphate in dogs [33–
35]; little is known about renal excretion and/or potential
reuptake of diﬀerent As metabolites.
1.3. Mechanisms of Action of As. InAs is a highly reactive
metalloid. AsIII toxicity is largely attributable to its ability to
r e a c tw i t hc r i t i c a ls u l f h y d r y lg r o u p so fm a n ye n z y m e s .T h e
complex of As with a given protein bestows selectivity to the
biological eﬀects of As [36] and As metabolites diﬀer in their
protein binding capacity: InAsIII has three coordination sites,
MMAIII has two, and DMAIII has only one [37]. A stable
structure only forms when As complexes with two sulfhydryl
groups in a single protein. For this reason, the stability and
speciﬁcity of binding between DMA and monothiols are less
than that formed between InAsIII or MMAIII and dithiols
[36]. Toxicities of AsV are related to its striking chemical
resemblance to phosphate. For example, AsV can serve as
a substrate for enzymes that normally utilize phosphate,
potentially resulting in disruption of normal biochemical
processes [38].
Although As is an established human carcinogen, the
carcinogenic mechanism of As is likely to be through a novel
process, as As is a poor mutagen in in vitro studies. As a
notable exception, Waalkes group has determined that in
utero As exposure during critical periods of development
results in various tumors in the adult oﬀspring, indicating
that in these circumstances As can act as a complete car-
cinogen. The carcinogenic mechanism of action of As is not
known, but may involve oxidative stress and clastogenicity
[39, 40]. Arsenic is considered to be a member of a class of
carcinogensknownasgeneinducers,orindirectcarcinogens,
due, in part, to its proposed inﬂuence on DNA methylation
[41]. Recent evidence also indicates that As exposure may be
associated with alterations in histone modiﬁcations [42–58]
and that in utero exposure is associated with alterations in
stem cell response to carcinogen exposure during adulthood
[59].
1.4. Arsenic Methylation as a Detoxiﬁcation Pathway. Despite
decades of research implicating As methylation as a detox-
iﬁcation pathway, the inﬂuence of As methylation on As
toxicity has been under intense investigation in recent years.
LandmarkworkbyStybloetal.[60]andPetricketal.[61,62]
in 2000 found MMAIII to be the most toxic metabolite both
in vitro and in vivo. Subsequent toxicological studies have
conﬁrmed that MMAIII and DMAIII are at least as cytotoxic
[63] and genotoxic [64–68]a sI n A s III. In contrast, data
suggesting that DMAV is a bladder carcinogen in rats [69]
has been discounted in terms of human relevance due to
the extraordinarily high doses employed [70]. Also, animal
models suﬀer limitations in that there are profound species
diﬀerences in As metabolism, and animals are less prone to4 Journal of Toxicology
develop cancer in response to As exposure than humans.
Based largely on cell culture studies, the relative toxicities
are thought to be MMAIII > DMAIII > InAsIII > InAsV >
MMAV >DMAV,withthequaliﬁcationthatDMAIII ishighly
unstable and is not likely present in signiﬁcant quantities in
vivo [21].
The relatively high toxicity of MMAIII leads to a critical
question as to whether the overall methylation process is one
of detoxiﬁcation or of bioactivation since this metabolite is
thought to be a requisite intermediate in the generation of
DMAV. Under conditions of chronic low-dose InAs expo-
sure, the extent to which MMAIII arising from endogenous
biosynthesis exists as a free moiety within the intracellular
milieuasopposedtothatwhichisboundtoGSH,AS3MT,or
other cellular proteins is an open question and would likely
inﬂuence its toxicity. Indirect evidence of a beneﬁcial eﬀect
of methylation comes from studies indicating a protective
role for folate and/or SAM or of enhanced As toxicity under
conditions of folate deﬁciency. For example, McDorman et
al. demonstrated that dietary folate deﬁciency enhances the
induction of As-induced micronuclei by 1.3- to 4.5-fold
as compared to folate suﬃcient mice at As doses of 2.4
to 10mg/kg via oral gavage [71]. Likewise, Ramirez et al.
[72] induced micronuclei formation in human lymphocytes
with 10µM sodium arsenite and found that micronuclei
formation was attenuated by the addition of 17nM SAM.
Folate deﬁciency has also been reported to enhance the
eﬀects of As on gene expression in a study employing skin
biopsies from K6/ODC mice, one of the few rodent models
sensitivetoAs-inducedtumorigenesis[73].Whilesuggestive,
these studies lack direct measures of As metabolites, and
alternative explanations for the observations cannot be ruled
out.
In human populations, case-control studies indicate that
individuals with relatively higher proportions of MMA(III+V)
and lower proportions of DMA in urine are at increased risk
for As-related health outcomes, including skin lesions, skin,
lung, and bladder cancers, peripheral vascular disease, and
atherosclerosis [5, 74–85]. Note that technology does not
yet allow for reliable speciation of MMAIII versus MMAV
as MMAIII is very readily oxidized to MMAV during sample
collection,storage,andprocessing.Someoftheabovestudies
were limited in that the number of cases was relatively small
(i.e., 26 to 76 cases) [75, 76, 78, 79] and while the odds
ratios werenot inclusive ofone, the95% conﬁdenceintervals
tended to be relatively wide (e.g., 1.7–34 for skin cancers)
[75]. Two larger studies include one case-control study of
urothelial carcinoma (N = 177 cases versus 488 controls)
in Taiwan and another study of skin lesions (N = 594
cases versus 1,041 controls) in Bangladesh. The Taiwan study
found that total urinary As, %InAs and %MMA all exhibited
signiﬁcant dose-dependent increased risk for urothelial
carcinoma, whereas %DMA was associated with decreased
risk [77]. The Bangladesh study found that %MMA in urine
was positively associated with risk for skin lesions in a dose-
dependent manner, while %DMA was inversely associated
withrisk[74].Thus,theweightofthehumanevidencefavors
the consensus that incomplete methylation of As to DMA
confers increased susceptibility to multiple adverse health
outcomes. However, these studies all suﬀer the common
limitation that As metabolites were assessed after disease
onset, bringing into question the issue of temporality. In
sum, although there appears to be an emerging consensus
among epidemiologists that complete methylation of As to
DMA is beneﬁcial, the lack of large scale population-based
studies analyzing prediagnostic biological samples renders
this consensus somewhat tenuous.
2. NutritionalInﬂuences on
Methylation Reactions
Methylation of As and numerous other substrates occurs
via one-carbon metabolism, a biochemical pathway impor-
tant in the biosynthesis of purines and thymidylate and
the remethylation of homocysteine (Hcys) to methionine
(Figure 2). Methionine is activated to SAM, which serves
as a methyl donor for a variety of methylation reactions,
including the methylation of As. Transmethylation reac-
tions generate s-adenosylhomocysteine (SAH), which can be
converted to Hcys. SAH is a strong inhibitor of most
methyltransferase enzymes, including AS3MT. One-carbon
metabolism is dependent upon folate, vitamin B12, and vita-
min B6 for the recruitment and transfer of methyl groups.
Other nutrients, including betaine, choline, riboﬂavin, and
serine also contribute to the availability of methyl groups
ultimately used in SAM biosynthesis.
2.1. Experimental Evidence of Nutritional Inﬂuences on As
Methylation and Toxicity. Early studies observed eﬀects of
methyl donor deﬁciency on As excretion and provide exper-
imental evidence that the well-characterized nutritional reg-
ulation of one-carbon metabolism can inﬂuence As methy-
lation and toxicity. In 1987, Vahter and Marafante reported
that methyl donor deﬁciency in rabbits induced by either
choline-, methionine- or protein-deﬁcient diets signiﬁcantly
decreased urinary excretion of As, mainly due to lower DMA
excretion. These diets also gave rise to increased retention
of As in tissues (e.g., lung) [86], suggesting longer half lives
and greater chemical reactivity of the InAs species. Similarly,
Tice et al. reported that methyl donor deﬁciency induced by
a choline-deﬁcient diet decreased total urinary As excretion
in mice by 28% as compared to mice on a choline-suﬃcient
diet, predominantly due to reduced urinary DMA [87]. This
was also accompanied by a shift in target organ As-induced
DNA damage from liver and bladder (sites of As methylation
and urinary As elimination, respectively) to skin [87], a
target tissue in which As has a high aﬃnity for the sulfhydryl
groups of keratin.
An elegant series of studies by Finnell’s group on As-
induced NTDs employed mice heterozygous or nullizy-
gous for folate binding proteins including Folbp-1, -2,
and reduced folate carrier (RFC) [88–91]. Each of these
binding proteins functions in cellular uptake of folate from
the circulation (Folbp1 and 2) and/or enterocytes (RFC).
While mice nullizygous for Folbp1 and RFC die in utero,
the heterozygotes and Folbp2−/− develop normally and
Folbp1 embryos can be rescued with folinic acid. The studyJournal of Toxicology 5
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vitamin B12 as a cofactor, the methyl group of 5-methyl-THF is transferred to homocysteine (Hcys), generating methionine and THF.
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homocysteine methyltransferase (BHMT). (5) Methionine adenosyltransferase activates methionine to form S-adenosylmethionine (SAM).
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protocols employed i.p. injections of sodium arsenate (30–
40mg/kg) on gestational days 7.5 and 8.5, that is, a critical
period for neural tube closure. These studies demonstrated
that for all genotypes studied (including wildtype), dietary
folate deﬁciency caused a reduction in total urinary As
excretion, primarily due to a reduction in DMA excretion.
Furthermore, folate-binding protein 2−/− mice were more
susceptible to As-induced NTDs, a phenotype that was
further exacerbated by a folate-deﬁcient diet [90].
Whilethesestudiesprovidestrongexperimentalevidence
that nutritional manipulation of one-carbon metabolism
inﬂuences As methylation, excretion, and toxicity, the As
doses were high, and the dietary deﬁciencies were severe.
Moreover, there are marked species variations in the eﬃ-
ciency of As methylation [92].
2.2. Nutritional Inﬂuences on As Methylation in Humans. As
noted, rodent models suﬀer two limitations: there are pro-
found species diﬀerences in As metabolism, both mice and
rats are extremely eﬃcient in methylation of As, and animals
are less prone to develop cancer in response to As exposure
than humans. Furthermore, it is diﬃcult to mimic chronic
low-dose population exposure levels using rodent models.
The earliest human data implicating nutritional inﬂuences
on methylation and toxicity of As came in the form of
isolated case reports. For example, there is an interesting case
study of a girl with MTHFR deﬁciency who developed severe
clinical signs and symptoms of As poisoning upon exposure
to an As-containing pesticide, whereas no other exposed
family members developed symptoms [93]. In 2002, in a
study of 11 families in Chile, Smith’s group reported intra-
family associations in As methylation. The father/mother
correlation for In As/(MMA+DMA) was low (r = 0.18).
However, adjustment for plasma folate or homocysteine
substantially increased the correlations (r = 0.33 and 0.55,
resp.) [94]. Although the authors did not conclude that
there was a signiﬁcant eﬀect of nutritional factors on As
methylation, the data were highly suggestive.
In 2005, this same group assessed dietary intake of 30
micronutrients by dietary questionnaire in a sample of 87
subjects from two As-exposed regions in the western USA.
They found that subjects in the lower quartile for dietary
protein, iron, zinc and niacin had higher %MMA and
lower %DMA than subjects in the higher quartile [95]. No
associations were found for dietary folate, but the study was6 Journal of Toxicology
conducted several years after mandatory folic acid forti-
ﬁcation of the USA food supply and therefore all of the study
subjects were essentially folate supplemented.
More recently, Vahter’s group analyzed plasma concen-
trations of folate, cobalamin, zinc, and ferritin in a cross-
sectional study of 442 pregnant women from Matlab,
Bangladesh. In their analyses, they ﬁrst stratiﬁed by As expo-
sure (tertiles of urinary As) and then compared %InAs,
%MMA, and %DMA across tertiles of plasma micronutrient
concentrations. In a multivariate adjusted model, only
%InAs was found to be lower with increasing plasma folate
concentrations and only among the highest As exposure sub-
group [96]. In a subsequent study in a subset of 324 women
from the same parent study who had urine samples available
at gestational weeks 8, 14, and 30, Vahter et al. examined
changes in As methylation during the course of pregnancy
and whether any observed changes were associated with
nutritional status. Gestational week was inversely associated
with the percentage of urinary InAs and positively associated
with the percentage of urinary MMA and DMA (P<0.001
for all). There were no observed associations between plasma
folate or vitamin B12 and the change in urinary %InAs,
%MMA, and %DMA over the course of pregnancy [97].
Although the authors concluded from these studies that nu-
tritional status had little inﬂuence on As methylation, this
is not surprising given that plasma folate concentrations
change dramatically over the course of pregnancy, intro-
ducing noise to the variable. Also, all of these women had
been given prenatal folic acid (400µg) starting at week 14
in addition to other vitamin and/or mineral supplements. In
addition, it is possible that other nutrients which were not
examined in this study, such as choline and betaine, play a
more substantial role in As methylation during pregnancy;
choline biosynthesis is signiﬁcantly upregulated by estrogen,
concentrations of which rise dramatically during pregnancy
[98].
Our group has conducted a series of studies in Bang-
ladesh on nutritional inﬂuences on As metabolism and tox-
icity. We ﬁrst evaluated the underlying prevalence of folate
and B12-deﬁciency and hyperhomocysteinemia (HHcys) in
a random sample of 1,650 Bangladeshi adults. This survey
revealed that the study population has an extremely high
prevalence of HHcys, particularly among males: 63% of
m a l e sa n d2 6 %o ff e m a l e sw e r ef o u n dt oh a v eh y p e r -
homocysteinemia (using NHANES cutoﬀso f≥11.4 and
10.4µmol/L, for males and females, respectively) [99]. The
data are consistent with a 2000 report in Lancet. In that
study of healthy males, plasma total homocysteine (tHcys)
concentrations were higher in Indian Asian men residing
in the UK than their white European counterparts [100].
Our survey also revealed modest but statistically signiﬁcant
negative correlations between water As and plasma folate
concentrations (r =− 0.13, P>0.0001), suggesting that As
may in some way negatively impact folate nutritional status.
We subsequently selected a subset of 300 participants
from the survey for measurement of urinary As metabolites
foracross-sectionalstudyontheassociationsbetweenfolate,
tHcys, and As methylation [101]. This subset was selected to
be representative of the study population for total urinary
As after excluding those identiﬁed as being cobalamin
deﬁcient. The results of these analyses revealed moderate
but signiﬁcant positive correlations between plasma folate
and the relative proportion of DMA (%DMA) in urine
and negative correlations between folate and both InAs and
MMA in urine (Spearman Correlations −0.12, −0.12, and
0.14, for %InAs, %MMA and %DMA, resp.; P<0.05 for
all). Concentrations of tHcys were positively correlated with
%MMA (r = 0.21, P<0.001) and negatively correlated with
%DMA (r =− 0.14, P<0.001).
In this same study, we made the serendipitous obser-
vation that urinary creatinine is negatively correlated with
%InAs and positively correlated with %DMA in urine (r =
−0.32 and 0.30, resp., P>0.0001); the correlations remain
equally robust with and without control for covariates
including body weight, age, and water or urine As concen-
t r a t i o n s .W eh a v ec o n ﬁ r m e dt h i so b s e r v a t i o ni ns e v e r a l
subsequent studies in Bangladesh [53, 102–104] and in an
unpublished analysis of data from adults in Mexico provided
from Drs. Uttam Chowdhury and H. Vasken Aposhian.
Smith’s group has subsequently reported similar ﬁndings in
West Bengal [105]. The underlying mechanism for this
observation is not readily apparent, but we note the substan-
tial role of creatine biosynthesis on consumption of SAM-
derived methyl groups [106] ,ar o l et h a ti sd o w n r e g u l a t e d
with increased dietary creatine intake.
In 2006, we reported the initial ﬁndings from our ran-
domized,controlledtrialoffolicacidsupplementation[103].
For this trial, 200 participants were randomly selected from
the550participantswhofellintothelowesttertileforplasma
folate in the survey of 1,650. Participants were excluded if
they were cobalamin deﬁcient, pregnant, or taking vitamin
supplements. Participants were randomly assigned to receive
folic acid (400µg/day, that is, the USA RDA) or placebo
for 12 weeks. Urinary As metabolites were measured at en-
rollment, after one week and after 12 weeks. Folic acid sup-
plementation resulted in an increase in the proportion of
total urinary As excreted as DMA (72% before and 79%
after) that was signiﬁcantly (P<0.0001) greater than that
in the placebo group, as was the reduction in %MMA (13%
before and 10% after, P<0.0001) and %InAs (15% before
and 11% after, P<0.001). Signiﬁcant treatment group dif-
ferences were also observed for %MMA and %DMA even
after just one week of the intervention.
Based on our understanding that As methylation facili-
tates urinary As elimination, and our observation that folic
acid supplementation increased As methylation, we hypoth-
esized that increased As methylation with folic acid supple-
mentation would lower blood As concentrations. Method-
ologic advances in our Trace Metals Core Laboratory per-
mitted us to test this hypothesis using blood samples from
our folic acid trial by measuring total As and As metabolites
in blood, where concentrations are an order of magnitude
lower (range: 3–29µg/L) than those in urine (8–780µg/L).
We measured As metabolites in blood for 130 participants,
that is, those participants from our previous trial who had
detectable levels of all As metabolites. Results revealed that
folicacidsupplementationresultedinadeclineintotalblood
As of 13.6 ±2.9% as compared to 2.5 ±3.2% for the placeboJournal of Toxicology 7
group (P = 0.01) [107]. The decline in blood As was largely
due to the decline in MMA in blood. Whereas total blood As
(i.e., InAs+MMA+DMA) declined, on average, by 1.7µg/L,
1.1µg/L of this was MMA; MMA declined by 22% from
baseline.
2.3. Nutritional Impact on Risk for As-Induced Health Out-
comes. In 2004, Smith’s group conducted a dietary recall
study in West Bengal, India, of 192 skin lesion cases and
192 age- and sex-matched controls. The results of this study
indicated that participants falling into the lowest quintile for
animal protein, calcium, ﬁber, and folate were at increased
risk for As-induced skin lesions [108]. In 2006, this group
reported results of a study of plasma concentrations of a
series of 17 metabolites (including a series of micronutrients
and cholesterol, glucose, glutathione, homocysteine, and
transthyretin) and risk for As-induced skin lesions; plasma
analyses were done on a subset of 180 of the original 192
cases. No statistically signiﬁcant odds ratios were observed
for any of the parameters studied, including folate and
homocysteine. However, approximately half of the samples
were stored at 4◦C overnight and not aliquoted and frozen
until the day after collection [109]. Since folate is highly
unstable and would likely be degraded under these con-
ditions, and homocysteine continues to be released into
plasma by red blood cells after sample collection, the plasma
concentrations for these (and other) metabolites cannot
be considered to be accurate due to the sample handling
procedures. Additional limitations include lack of statistical
control for diﬀerences in As exposure which diﬀered by case-
control status and lack of As metabolite data.
One of the strongest studies to date on the impact of
nutritional status on risk for As-induced health outcomes
is the recent aforementioned case-control study of 177
urothelial carcinoma cases and 488 controls in a population
in Taiwan exposed to low concentrations of As in drinking
water. This study found that higher %DMA in urine and
higher plasma folate concentrations were associated with
decreased risk. In a multivariate-adjusted model, the odds
ratios (95% CI) for increasing quartiles of plasma folate con-
centrations were 1.0 (referent), 0.33 (0.20–0.54), 0.22 (0.13–
0.38), and 0.09 (0.04–0.19), Ptrend < 0.0001. Furthermore,
a signiﬁcant interaction was observed between urinary As
proﬁles and plasma folate in aﬀecting urothelial carcinoma
risk [77].
We have conducted a nested-case control study of 274
skin-lesion cases individually matched to controls for gender
and age (within 5 years) and frequency matched for water
As (within 100µg/L). The results of this study indicate
that folate deﬁciency and HHcys are both associated with
increasedriskforskinlesions[52],asisgenomichypomethy-
lation of leukocyte DNA and low urinary creatinine [Odds
ratios (95% conﬁdence interval) were 1.8 (1.1–2.9) for
plasma folate <9nmol/L, 1.7 (1.1–2.6) for HHcys, 1.8 (1.2–
2.8) for DNA methylation < median, and 0.7 (0.5–0.8) for
a fold increase in urinary creatinine]. Clearly, clariﬁcation
of the mechanisms underlying urinary As and creatinine
interactions warrants further study.
3. Conclusions
The known health eﬀects of long-term exposure to As
include an array of health outcomes and increased risk
for mortality. In countries with widespread contamination
of drinking water, such as Bangladesh, the full impact of
t h i se x p o s u r em a yn o tb ea p p a r e n tf o ry e a r st oc o m e .
Although there has been considerable debate as to whether
As methylation is a bioactivation or detoxiﬁcation pathway,
the collective body of evidence from both laboratory and
epidemiologic research has clariﬁed several points. First, As
methylation to DMA is primarily catalyzed by AS3MT and
plays a key role in modulating As excretion and toxicity.
Second, a lower capacity to methylate As to DMA, as
evidenced by higher proportions of InAs and MMA in urine
and blood, is associated with increased risks of several As-
associated diseases. Lastly, the methylation and elimination
of As are inﬂuenced by nutrients involved in one-carbon
metabolism, especially folate. Further research is needed
to determine whether other nutrients similarly inﬂuence
As methylation and at what levels of intake the greatest
beneﬁt can be obtained. While clearly As-mitigation is
of primary importance, nutritional manipulation of one-
carbon metabolism may provide an additional approach for
lessening the burden of disease resulting from long-term As
exposure.
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